secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K/A
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000886163-23-000089
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q3 adj EPS $1.02 beats, raises 2023 guidance; restates prior net loss per share to ($0.59)
--------------------------------------------------------------------------------

- Q3 total revenue $32.9M (down from $59.2M YoY, no COVID-19 sales); adjusted EPS $1.02 vs $0.60 YoY.
- Raised 2023 revenue guidance to $126-129M (from $124-126M) and adjusted EPS to $5.25-5.40 (from $5.10-5.25).
- 8-K/A correction: $3.2M derivative asset from Pelican divestiture changed sale from ($1.1M) loss to $2.1M gain; net loss per share improved to ($0.59) from ($0.74).
- Invested >$75M in Q3/Q4 in Tolerance, Ovid, Novan, Primrose; acquired 13% royalty interest in soticlestat (up to $86M milestones).
- Cash and short-term investments $190.5M at Sep 30, 2023; new $75M revolving credit facility with Citibank.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/0000886163-23-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/lgnd-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer